Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation- DALY 2-EU Trial

被引：1

作者：

Borchmann, Peter ^{[1
]}

Vandenberghe, Peter ^{[2
]}

Urbano-Ispizua, Alvaro ^{[3
]}

Haioun, Corinne ^{[4
]}

Lemonnier, Francois ^{[4
]}

Griskevicius, Laimonas ^{[5
]}

Maury, Sebastien ^{[4
]}

Holtkamp, Silke ^{[6
]}

Friedrichs, Birte ^{[6
]}

Zadoyan, Gregor ^{[6
]}

Hanssens, Linda ^{[6
]}

Overstijns, Toon ^{[6
,7
]}

Assenmacher, Mario ^{[7
]}

Bethke, Ulf ^{[7
]}

Buerger, Iris ^{[7
]}

Reer, Olaf ^{[7
]}

Jaeger, Ulrich ^{[8
]}

Kersten, Marie Jose ^{[9
,10
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med 1, Cologne Lymphoma Working Grp, Cologne, Germany

[2] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium

[3] Hosp Clin Barcelona, Inst Clin Malalties Hematol & Oncol ICMHO, Barcelona, Spain

[4] Henri Mondor Univ Hosp, AP HP, Creteil, France

[5] Vilnius Univ Hosp Santaros Klin, Vilnius, Lithuania

[6] Miltenyi Biomed GmbH, Bergisch Gladbach, Germany

[7] Miltenyi Biotec BV & Co KG, Bergisch Gladbach, Germany

[8] Univ Hosp Vienna, Dept Hematol & Hemostaseol, Vienna, Austria

[9] Amsterdam Univ Med Ctr, Locat Univ Amsterdam, Amsterdam, Netherlands

[10] Canc Ctr Amsterdam, Amsterdam, Netherlands

来源：

关键词：

D O I：

10.1182/blood-2022-164650

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：12784 / 12785

页数：2